Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | Werner syndrome, RecQ helicase-like | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0015 | 0.0671 | 0.5 |
Schistosoma mansoni | blooms syndrome DNA helicase | 0.0023 | 0.1201 | 0.4496 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0012 | 0.042 | 0.4422 |
Echinococcus multilocularis | bloom syndrome protein | 0.0029 | 0.1637 | 0.5407 |
Trichomonas vaginalis | DNA helicase recq, putative | 0.0029 | 0.1637 | 1 |
Leishmania major | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0015 | 0.0671 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2671 | 1 |
Entamoeba histolytica | recQ family helicase, putative | 0.0015 | 0.0671 | 0.2514 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.2671 | 1 |
Echinococcus granulosus | bloom syndrome protein | 0.0029 | 0.1637 | 0.5407 |
Brugia malayi | Bloom's syndrome protein homolog | 0.0029 | 0.1637 | 0.5407 |
Schistosoma mansoni | DNA helicase recq1 | 0.0012 | 0.042 | 0.1571 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.2671 | 1 |
Plasmodium falciparum | ADP-dependent DNA helicase RecQ | 0.0025 | 0.1385 | 1 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0012 | 0.042 | 0.4422 |
Treponema pallidum | ATP-dependent DNA helicase | 0.0006 | 0 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.2671 | 1 |
Trypanosoma cruzi | ATP-dependent DEAD/H DNA helicase recQ, putative | 0.0015 | 0.0671 | 0.5 |
Trichomonas vaginalis | DNA helicase recq1, putative | 0.0029 | 0.1637 | 1 |
Giardia lamblia | Sgs1 DNA helicase, putative | 0.0012 | 0.042 | 0.5 |
Loa Loa (eye worm) | RecQ helicase | 0.0029 | 0.1637 | 0.1271 |
Brugia malayi | hypothetical protein | 0.0043 | 0.2671 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.2671 | 1 |
Schistosoma mansoni | DNA helicase recq5 | 0.0012 | 0.042 | 0.1571 |
Plasmodium vivax | ADP-dependent DNA helicase RecQ, putative | 0.002 | 0.0966 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2671 | 1 |
Toxoplasma gondii | ATP-dependent DNA helicase, RecQ family protein | 0.0019 | 0.0949 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2671 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.2671 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.92 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 3.9811 uM | PubChem BioAssay. qHTS for Inhibitors of WRN Helicase. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.